On Monday, Shares of BP p.l.c. (NYSE:BP), lost -0.98% to $42.39.
BP, plans to sell part of its oil project off southern Australia, before an exploration campaign that’s slated to start late next year at a cost of more than A$1 billion ($800 million), according to Bloomberg.
BP wants to cut its stake to between 40 percent and 50 percent from 70 percent, with the sales process starting in the second half this year, Bryan Ritchie, vice president of exploration for Asia Pacific, told reporters Tuesday in Melbourne. Statoil ASA owns the rest of the project in the Great Australian Bight, Bloomberg Reports.
BP p.l.c. operates as an integrated oil and gas company worldwide. It operates in three segments: Upstream, Downstream, and Rosneft. The Upstream segment engages in the oil and natural gas exploration, field development, and production; midstream transportation, and storage and processing; and marketing and trade of natural gas, counting liquefied natural gas (LNG), and power and natural gas liquids (NGL).
Shares of Celgene Corporation (NASDAQ:CELG), inclined 0.73% to $116.37, during its last trading session.
Celgene Corporation, declared that a post-hoc subgroup analysis of a double-blind, placebo-controlled, randomized, multicenter phase II trial of GED-0301 (mongersen) in patients with active Crohn’s disease was presented at Digestive Disease Week (DDW) in Washington, D.C.
The primary findings of the phase II trial, which enrolled 166 adult patients with active Crohn’s disease, defined as Crohn’s Disease Activity Index (CDAI) scores >220 to ≤400, were published in the March 19, 2015 issue of The New England Journal of Medicine. Patients in the trial were treated for two weeks with either placebo or one of three doses of GED-0301 (10 mg, 40 mg or 160 mg tablets, once daily) and then followed for an additional 10 weeks. The presentation at DDW retrospectively examined certain subgroups of patients in the trial.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally.
At the end of Monday’s trade, Shares of Tesla Motors, Inc. (NASDAQ:TSLA), lost -0.04% to $248.75.
The Tesla Model S was a breakthrough. The first long-range luxury electric car. Breathtaking acceleration. A 16-inch LED center display screen.
So after all that amazing technology was poured into one car, owners continue to be befuddled by a techno-glitch involving a feature as old as the car itself: the door handle.
Faulty door handles have been one of the issues that owners have complained about since the Model S was introduced. Even now, almost three years after its introduction, they are still a problem, as Consumer Reports just discovered on the $127,000 performance version of the Model S that it just bought.
Tesla Motors, Inc. designs, develops, manufactures, and sells electric vehicles, electric vehicle powertrain components, and stationary energy storage systems in the United States, China, Norway, and internationally. It also provides development services to develop electric vehicle powertrain components and systems for other automotive manufacturers.
Finally, Cree, Inc. (NASDAQ:CREE), ended its last trade with 5.83% gain, and closed at $31.48.
Cree, declared that Cree’s wholly owned Power and RF partner has presented a draft registration statement on a confidential basis to the U.S. Securities and Exchange Commission for a potential initial public offering of the partner’s Class A common stock.
The type and number of shares of stock to be sold and the price range for the projected initial public offering has not yet been determined, although Cree intends to remain the majority stockholder of the partner post offering. The initial public offering is predictable to commence after the Securities and Exchange Commission completes its review process, subject to market and other conditions. The Power and RF partner is raising capital to invest directly in the business to support targeted future growth.
The offering would enable Cree administration to focus on Cree’s LED and Lighting businesses, while also creating a dedicated focus on the Power and RF business. The company believes that this transaction should allow Cree shareholders to better realize the full value of both businesses.
Cree, Inc. develops, manufactures, and sells lighting-class light emitting diode (LED), lighting, and semiconductor products for power and radio-frequency (RF) applications in the United States, China, Europe, South Korea, Japan, Malaysia, Taiwan, and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
